Printer Friendly Printer Friendly   | Text Size Decrease Text Size Increase Text Size

Press Releases

Showing 1-35 of 220
First 1   2   3   4   5   6   7   Next   Last

2010
February

2/8/10 Abbott Submits New Automated Ovarian Cancer Test for U.S. Approval
2/1/10 Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer

January

1/27/10 Abbott Reports Double-Digit Sales and Earnings Growth in Fourth Quarter; Issues Strong Earnings Outlook for 2010
1/25/10 Abbott Submits New HIV Test to FDA for Expedited Review
1/18/10 Updated Abbott Statement: To Help Respond to Growing Health Crisis, Abbott Increases Aid to $2.5 Million for Haiti Relief and Recovery Efforts
1/14/10 Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
1/13/10 Abbott to Provide $1 Million in Funding, Products to Help Address Health Needs in Haiti
1/8/10 Abbott's XIENCE V® Approved in Japan – Second Largest Drug Eluting Stent Market Worldwide
1/4/10 Abbott to Present at J.P. Morgan Healthcare
1/4/10 Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2009 Earnings
1/4/10 New Abbott Gene-Based Test for Colorectal Cancer Receives CE Mark

2009
December

12/14/09 Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems
12/11/09 Abbott Declares 344th Consecutive Quarterly Dividend
12/10/09 Abbott Seeks FDA Approval of New Dosage Strengths of SIMCOR® (niacin extended-release/simvastatin)
12/2/09 Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist
12/2/09 Abbott and the Abbott Fund Honored With Corporate Citizenship Award for International Community Service

November

11/19/09 The Deal Names Abbott Top Dealmaker for Second Consecutive Year
11/17/09 Abbott to Develop New Heart Failure Test on ARCHITECT® Immunochemistry Diagnostics Platform
11/16/09 Abbott Announces Positive Three-Year Data on Its Fully Bioabsorbable Stent Technology, Initiates Large-Scale International Trial
11/15/09 Abbott Statement on ARBITER 6 - HALTS Results and Abbott's Niaspan (niacin extended-release)
11/12/09 Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
11/12/09 New Web Sites Educate About Triglycerides and HDL Cholesterol
11/3/09 President of Tanzania and the Abbott Fund Dedicate Modern Emergency Medical Department
11/2/09 Abbott Completes Acquisition of Evalve, Inc.
11/2/09 Abbott's XIENCE PRIME™ and XIENCE V® Receive Indications in Europe for Treatment of Patients with Diabetes
11/2/09 Abbott Saving 1 Billion Gallons of Water Annually

October

10/29/09 Abbott Receives Sustainability Award for Continued Efforts to Protect the Environment in Illinois
10/20/09 FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
10/20/09 Abbott Completes Visiogen Acquisition
10/19/09 ZonePerfect Indulgence™ Nutrition Squares Give Chocolate Lovers a Sensible Sweet-Tooth Option
10/14/09 Abbott Reports 16.5 Percent Earnings Growth in Third Quarter; Raises Earnings Guidance for 2009
10/6/09 Novel Abbott Test That Aids in the Early Diagnosis of Acute Kidney Injury (AKI) Receives CE Mark

September

9/30/09 Abbott Cuts Use of Oil and Coal by 35 Percent
9/28/09 Abbott to Acquire Solvay Pharmaceuticals Business
9/24/09 Abbott Hosts Conference Call for Third-Quarter Earnings
First 1   2   3   4   5   6   7   Next   Last

Narrow by Year

Narrow to Show

Survey

We would appreciate your feedback on our News and Media section. Please participate in our online survey.

Newsfeed

RSS

Subscribe to Abbott's Newsfeeds and get up-to-the-minute news from all of Abbott's businesses.


Home | Select a Country | Site Map | Contact Us | Privacy Policy | Terms of Use

Copyright © 2006, 2010 Abbott Laboratories. Abbott Park, Illinois, U.S.A.


Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott Laboratories, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Laboratories, except to identify the product or services of the company.